Although PD-1 blockade has transformed cancer treatment, a deeper understanding of tumor immunobiology and inhibitory mechanisms are needed to take immunotherapy to the next level. This webinar will cover topics including the cell types that express key B7 family members and their receptors including PD-L1, B7-H3, B7-H4 and PD-1 and discuss whether these findings align with the traditional views for what is going on in the tumor microenvironment. In addition, it will cover unexpected immunoregulatory mechanisms that we have found focussing on innate lymphoid cells.
PRESENTER
Dr. Pamela Ohashi received her Ph.D from the University of Toronto with Dr. Tak Mak, and did her post-doctoral training at the University of Zurich with the Nobel Laureate Dr. Zinkernagel, and Dr. Hans Hengartner. She is a Senior Scientist and Director of the Tumor Immunotherapy Program at the Princess Margaret Cancer Centre, and a Professor in the Department of Immunology at the University of Toronto. Her interests include understanding CD8+ T cell biology and mechanisms that regulate anti-tumor immunity.
MODERATOR
Dr. Abdallah Badou is a Professor of Immunology at the Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco. Dr. Badou has completed his PhD in Immunology in 1998 at Paul Sabatier University (Toulouse, France). His research topics are related to the study of the immune response in inflammation and cancer. He is the Secretary General of the Moroccan Society of Immunology (SMI) and Treasurer of the Federation of African Immunological Societies (FAIS).
